The natural flow motion for pumps
The Wavera® Technology
Essential yet invisible, pumps are everywhere
Pumps consume 10% of worldwide electricity production — as much as the digital industry with its data centres and terminals combined — and represent up to 80% of the energy costs of processes in industries such as water treatment and food and beverage production. Furthermore, 10% of the world’s pumps are renewed every year.
The Wavera® undulating membrane can be adapted to all types of pumps in response to the market needs: costs, consumption, size and durability.
The Wavera® technology consists in using a linear motor to move a flexible membrane whose undulating movement, like the one of a fish’s fin, propels the fluid from the membrane’s excited side (upstream) to its free side (downstream).



Advantages


Up to 30% power saving
Lighter and smaller


Optimal on several operating points
Self-priming




Continuous flow (or possibility of pulsation)

Very rapid response time (12 milliseconds)

40 times less fluid shearing
High hydraulic/mechanical efficiency (80%)


Robust (no breakable parts: shaft, bearings, valve...)
Lower maintenance and power consumption costs
Patented technology
Unique in today's market
Markets
![]() Car industry80 Million of cars (2015) | ![]() Medical | ![]() Basic ChemistryUSD 3,8 Billion / year (2015) | ![]() Residential buildingsUSD 3,6 Billion / year | ![]() Dying out of buildingsUSD 2 Billion / year (2015) |
---|---|---|---|---|
![]() Food & beveragesUSD 2,9 Billion / year (2015) | ![]() Water treatmentUSD 5,4 Billion / year (2015) | ![]() Electrical appliances50 Million pumps / year (2015) | ![]() Aeronautics80 000 fills / day | ![]() AgricultureUSD 2,4 Billion / year (2015) |
![]() OilUSD 6,2 Billion / year (2015) | ![]() General industryUSD 2,9 Billion / year (2015) |
About Us


OUR STORY
AMS R&D was created by Erik Guillemin (Founding President) in order to develop the possibilities of the Wavera® undulating membrane fluid propulsion technology invented by Jean-Baptiste Drevet (engineer from the Arts et Métiers), for which AMS R&D owns all patents and technological expertise.
OUR TECHNOLOGY
Each Wavera® pump comprises three innovative parts :
-
the membrane, the heart of the Wavera® technology, which propels the fluid;
-
the linear motor, whose up-and-down motion gives the membrane its undulation;
-
the electronics, which control the linear motor and thereby, the pump.
OUR VISION

The application fields targeted in the short term by AMS R&D cover the medium and low pressures, where are present different technologies, such as centrifugal, conventional membrane or peristaltic pumps. These pumps are used in all industrial sectors, and represent a global park of several billion units, of which hundreds of millions are renewed annually.
AMS R&D is licensing its Wavera® technology to pump manufacturers to expand this energy efficient system as widely as possible.
Partnerships
AMS R&D is currently partnering with leading leaders in :

pharmaceutical

nuclear

medical


automobile
CorWave : MedTech Start-up
develops cardiovascular pumps based on Wavera® technology in the area of "Medical Cardiovascular".
This breakthrough technology propels all fluids (including blood) thanks to its undulating membrane.
CorWave's Left Ventricular Assist Device (LVAD) uses this Wavera® technology with a disk membrane, replacing the high shear rate turbine of current centrifugal pumps.
The Wavera® membrane is much less traumatic to the blood, reducing the complications of coagulation and bleeding. The high frequency operation of the CorWave pump ensures pulsatile flow that mimics the action of the native heart.
The currentand existing LVAD devices provide only a continuous flow without significant pulses, due to the high inertia of their rotors. The Wavera® membrane also has low power consumption and its small size will facilitate total implantation by integrating a wireless energy transfer system.


In October 2016, CorWave SA finalized a € 15.5m fund raising to finance the development of the new generation of LVAD "Neptune" pumps and the "Nemo" minimal invasive implantable heart pump.
AMS R & D SAS is one of the historic shareholders of this promising MedTech start-up.
CorWave has a second ongoing development for percutaneous ventricular assist devices (PVAD) based on a tubular version of the Wavera® membrane. CorWave brings a breakthrough technology to these two rapidly growing markets, estimated at a potential global value of several billion euros.
more information on :
Laboratory :
24 rue de l'Est
75020 Paris
FRANCE
Contact


MENU
ADDRESSES
Head quarter :
AMS R&D
2, rue Suzanne Ruelle
77240 Seine-Port
FRANCE
